Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 14, 2025; 31(14): 103267
Published online Apr 14, 2025. doi: 10.3748/wjg.v31.i14.103267
Immune therapies in intermediate-advanced unresectable hepatocellular carcinoma: Changing the therapeutic landscape
Sagnik Biswas, Arghya Samanta
Sagnik Biswas, Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi 110029, India
Arghya Samanta, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India
Author contributions: Samanta A designed the overall concept and outline of the manuscript; did literature review and critical revision of the manuscript; Biswas S did the literature review, wrote the initial manuscript draft, contributed to the editing of the manuscript. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Arghya Samanta, MD, Assistant Professor, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, Uttar Pradesh, India. arghyasamanta2905@gmail.com
Received: November 14, 2024
Revised: March 13, 2025
Accepted: March 19, 2025
Published online: April 14, 2025
Processing time: 148 Days and 17.9 Hours
Core Tip

Core Tip: Hepatocellular carcinoma is often identified in advanced cases and is associated with poor survival. Combination therapies such as immune checkpoint inhibitors or tyrosine kinase inhibitors along with interventional therapies are proposed to enhance the sensitivity of these tumors to drug therapy and increasing rates of clinical response. While such an approach has a robust pathophysiological basis, the clinical data on this approach is evolving and needs large multicentric studies. Results from early observational data on combination therapies is encouraging.